Αποτελέσματα Αναζήτησης
20 Μαΐ 2024 · In 2020, ASCO published a guideline on the selection of optimal adjuvant chemotherapy and targeted therapy for breast cancer. 1 This is a rapid recommendation update of that guideline that addresses, in turn, the adjuvant use of the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors abemaciclib and ribociclib in patients with stage II and III ...
14 Απρ 2021 · Breast cancers are the commonest solid cancer for Port placement. In our evaluation patients having chemotherapy ports were less worried about the upcoming chemo procedures because of...
Current Personalized Treatments for Breast Cancer: Strengths and Weaknesses. The current strategies of treatment are principally based on the tumor progression and BC molecular subtypes in order to offer the most personalized treatment for BC patients. The algorithm of BC treatment is represented in Figure 2.
The National Comprehensive Cancer Network (NCCN) guidelines for the treatment of breast cancer describe numerous recommended adjuvant chemotherapy regimens, including sequential anthracycline-cyclophosphamide and taxane (AC-T); concurrent anthracycline-cyclophosphamide and taxane (ACT); anthracycline-cyclophosphamide without taxane (AC ...
17 Μαρ 2007 · In our institutions, we discuss with our patients the option to keep their port systems for as long as 2 years after adjuvant breast cancer therapy owing to the increased risk of relapse within this period, in particular in high-risk patients.
25 Σεπ 2024 · This study analyzes the development, benefits, trial evidence, and price of new breast cancer drugs with US Food and Drug Administration (FDA) approval. We identified 26 drugs with 42 FDA-approved indications for early and metastatic breast cancer (2000–2023).
This study confirms that for women with early-stage breast cancer, at sufficient risk of recurrence and fit enough to be offered chemotherapy, combination anthracycline and taxane chemotherapy provides larger benefit than either drug alone.
